EGYPT —The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded a project funding grant of up to $16.5 million to Minapharm Pharmaceuticals and Chemical Industries S.A.E. to advance a novel candidate vaccine against Bundibugyo ebolavirus into early-stage clinical evaluation. Under the terms of the agreement, the capital will fund project activities required to progress the candidate from preclinical development through a Phase 1 clinical trial designed to evaluate safety and immunogenicity, with trial execution expected to take place in Africa.
Designed by Minapharm's Berlin-based subsidiary ProBioGen AG on its proprietary MVA-CR19 vector platform, the vaccine candidate represents a key milestone in multi-stage development efforts addressing a disease that has infected thousands in the Democratic Republic of the Congo. Under the operational structure, ProBioGen will handle Good Manufacturing Practice production of the recombinant drug substance in Germany, followed by drug product formulation at Minapharm's facility in Cairo, Egypt. The agreement further outlines a eventual technology transfer intended to establish fully localized end-to-end manufacturing capabilities within Egypt.
This development comes as global public health entities intensify efforts to mitigate biological threats and strengthen regional response capabilities across the African continent. By targeting a specific virus strain responsible for severe hemorrhagic fever outbreaks, the initiative addresses a crucial gap in global epidemic preparedness where commercial incentives for vaccine development have historically lagged behind public health necessity.
For investors and industry participants, the agreement underscores the strategic model of utilizing non-dilutive development grants to de-risk early-stage biopharmaceutical assets. While the initial capital does not represent commercial revenue or guaranteed profits for Minapharm, successful execution of Phase 1 clinical milestones positions the firm to receive potential follow-on backing for late-stage efficacy trials, emergency use authorizations, and eventual commercial registration across international jurisdictions.
